Company profile
Regeneron Pharmaceuticals
Biotechnology / diversified
Share price · REGN
$810.24+180.56 (+28.67%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(31 total)
31Total Assets
7Approved
5Phase 3 / Filed
19Phase 1–2 / Early
13Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Aflibercept(Eylea) | Approved | VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic | Age-Related Macular Degeneration |
Alirocumab(Praluent) | Approved | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
dupilumab(Dupixent) | Approved | IL-4R-alphaMonoclonal antibody | Atopic DermatitisNon-Small Cell Lung CancerAsthma |
Evinacumab(Evkeeza) | Approved | ANGPTL3Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
| Approved | BCMA x CD3Monoclonal antibody | Multiple Myeloma | |
| Approved | IL-6 receptorMonoclonal antibody | Rheumatoid Arthritis | |
| Phase 3 | Complement C5RNA / oligonucleotide | Age-Related Macular Degeneration | |
| Phase 3 | IL-33Monoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary Disease | |
| Phase 3 | Leptin receptorMonoclonal antibody | Obesity | |
| Phase 3 | Complement C5Monoclonal antibody | Age-Related Macular Degeneration | |
REGN1908-1909No recent activity | Phase 3 | Fel d 1 (major cat allergen protein)Monoclonal antibody | Asthma |
| Phase 2 | Antisense oligonucleotide (metabolic)RNA / oligonucleotide | Chronic Kidney DiseaseAtherosclerotic Cardiovascular Disease | |
| Phase 2 | CIDEB | MASH / NASH | |
| Phase 2 | HSD17B13 | MASH / NASH |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.